Accelerated Adoption of Minimally Invasive Procedures to Propel Tissue Ablation Market

Published Date : Apr 10, 2017

ALBANY, New York, April 10, 2017 - has announced the addition of a new report, titled “Global Tissue Ablation Market 2017-2021” to its offering. The in-depth study on the global tissue ablation market provides an insight into the current market outlook, key drivers and restraints, market share and size of end users, prominent trends and emerging opportunities, and competitive landscape. The research reports highlights technological advances in tissue ablation expected to boost the adoption of these devices. 

The report takes a closer look at the strategies adopted by various manufacturers that are expected to fuel adoption rate among various end users. The study also evaluates the crucial factors that will impact the revenue size of key players in major regions such as the Americas, Europe, and the Middle East, and Africa (EMEA). Furthermore, recent developments in the medical devices and healthcare industries expected to impact the competitive landscape in major regions are covered in the study. 

Growing at a steady pace, the global market for tissue ablation is expected to rise at a CAGR of 9.91% from 2017 to 2021. The soaring demand for minimally-invasive procedures to treat, modify, and destroy tumors has propelled the tissue ablation market. The increasing popularity of non-invasive treatment modalities is fuelled by the several advantages over other methods: reduced hospital stays, minimized risk of infection, less post-operative complications, and faster convalescence. A large number of medical device manufacturers are conducting training programs for clinicians involved in tissue ablation procedures. This is expected to bolster the uptake of the devices across various medical care facilities. 

 For Sample Copy, click here:

Several manufacturers are working actively to bring innovations in tissue ablation devices, which can enable physicians to optimize the volume of tissue ablated in the treatment of peripheral vascular disease and the field of oncology. This is expected to fuel the market along the forecast period. The delivery of various cost-effective solutions is expected to provide a fillip to the market. Furthermore, the spiraling demand for ablation procedures for the treatment of a number of chronic diseases, such as cardiac arrhythmias and various cancer types, is anticipated to open up lucrative avenues in the coming years.

Geographically, the Americas accounted for a major share in the tissue ablation market in 2016 and is anticipated to maintain its dominance throughout the forecast period. The substantial growth of the regional market is attributed to a rise in geriatric population, increasing prevalence of chronic diseases, and growing adoption of minimally invasive procedures in therapeutics.

The tissue ablation market is intensely competitive and is characterized by the presence of a large number of regional as well as global players. Vendors are increasingly focusing on numerous evidence-based clinical studies to vouch for the efficacy and performance of their offerings. Several manufacturers are adopting product differentiation as a strategy by bundling two or more products that seek to enhance the performance of the devices, catalyzing their uptake among end users.

Leading vendors in the global tissue ablation market include Boston Scientific Corporation, Johnson & Johnson, St. Jude Medical, Medtronic, Abbott Laboratories, Acoustic Medsystems, Bovie Medical, CSA Medical Inc., and Alcon.

To order report Call Toll Free: 866-997-4948 or send an email on